NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Shareholder Letter Highlighting Oncoprex(TM) Progress, License Agreement for a Diabetes Drug Candidate and Other Achievements
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progress with Oncoprex(TM), its lead drug candidate with an initial targeted indication for non-small cell lung cancer (“NSCLC”), its license agreement for a diabetes gene therapy drug candidate, as well as other operational and business achievements. A digital copy of the letter can be found on the Company’s website.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progress with Oncoprex(TM), its lead drug candidate with an initial targeted indication for non-small cell lung cancer (“NSCLC”), its license agreement for a diabetes gene therapy drug candidate, as well as other operational and business achievements. A digital copy of the letter can be found on the Company’s website.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer